Becton Dickinson and Company (BDX)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $59.39B
Last updated: Nov 17, 2026 at 11:05 AM ET
Becton Dickinson and Company (BDX) Earnings: Report Dates and Results
Becton Dickinson and Company (BDX) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Becton Dickinson and Company reported EPS of $4.15, above the $4.06 estimate. It beat the EPS estimate in each of the last 12 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BDX has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.2% below the $2.91 reported for the quarter ended Dec 31, 2025.
BDX Earnings Call
The latest BDX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BDX beat 36, missed 1 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 43.99% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.15 | $4.06 | $4.03 - $4.12 | +2.22% | Beat | +4.8% | 14 | N/A | Nov 5, 2026 | N/A |
| Jun 30, 2026 | $3.23 | $3.14 | $3.06 - $3.19 | +2.87% | Beat | -12.2% | 12 | 9 up, 2 down | Aug 6, 2026 | $4.98B |
| Mar 31, 2026 | $2.90 | $2.77 | $2.76 - $2.80 | +4.69% | Beat | -13.4% | 12 | N/A | May 7, 2026 | $4.71B |
| Dec 31, 2025 | $2.91 | $2.80 | $2.79 - $2.85 | +3.93% | Beat | -15.2% | 10 | 1 up, 0 down | Feb 9, 2026 | $5.25B |
| Sep 30, 2025 | $3.96 | $3.91 | $3.87 - $3.95 | +1.28% | Beat | +3.9% | 11 | 0 up, 0 down | Nov 6, 2025 | $7.47B |
| Jun 30, 2025 | $3.68 | $3.42 | $3.35 - $3.50 | +7.60% | Beat | +5.1% | 11 | 0 up, 4 down | Aug 7, 2025 | $4.73B |
| Mar 31, 2025 | $3.35 | $3.28 | $3.22 - $3.31 | +2.13% | Beat | +5.7% | 12 | 2 up, 0 down | May 1, 2025 | $4.48B |
| Dec 31, 2024 | $3.43 | $2.99 | $2.90 - $3.13 | +14.72% | Beat | +28.0% | 12 | 0 up, 1 down | Feb 5, 2025 | $5.17B |
| Sep 30, 2024 | $3.81 | $3.77 | $3.74 - $3.83 | +1.06% | Beat | +11.4% | 14 | 1 up, 0 down | Nov 7, 2024 | $5.44B |
| Jun 30, 2024 | $3.50 | $3.31 | $3.27 - $3.37 | +5.74% | Beat | +18.2% | 14 | 0 up, 0 down | Aug 1, 2024 | $4.99B |
| Mar 31, 2024 | $3.17 | $2.97 | $2.92 - $3.02 | +6.73% | Beat | +10.8% | 13 | 1 up, 0 down | May 2, 2024 | $5.04B |
| Dec 31, 2023 | $2.68 | $2.40 | $2.37 - $2.48 | +11.67% | Beat | -10.1% | 12 | 0 up, 0 down | Feb 1, 2024 | $4.71B |
| Sep 30, 2023 | $3.42 | $3.43 | $3.32 - $3.52 | -0.29% | Miss | +24.4% | 13 | 0 up, 1 down | Nov 9, 2023 | $5.09B |
| Jun 30, 2023 | $2.96 | $2.91 | $2.86 - $3.00 | +1.72% | Beat | +11.3% | 14 | 3 up, 0 down | Aug 3, 2023 | $4.88B |
| Mar 31, 2023 | $2.86 | $2.75 | $2.70 - $2.78 | +4.00% | Beat | -10.1% | 13 | 0 up, 0 down | May 4, 2023 | $4.82B |
| Dec 31, 2022 | $2.98 | $2.68 | $2.57 - $2.80 | +11.19% | Beat | -18.1% | 13 | 1 up, 0 down | Feb 2, 2023 | $4.59B |
| Sep 30, 2022 | $2.75 | $2.74 | $2.69 - $2.85 | +0.36% | Beat | +6.2% | 14 | 0 up, 1 down | Nov 10, 2022 | $4.76B |
| Jun 30, 2022 | $2.66 | $2.50 | $2.45 - $2.58 | +6.40% | Beat | -2.9% | 13 | 1 up, 0 down | Aug 4, 2022 | $4.64B |
| Mar 31, 2022 | $3.18 | $2.95 | $2.75 - $3.12 | +7.80% | Beat | -0.3% | 14 | 0 up, 0 down | May 5, 2022 | $4.75B |
| Dec 31, 2021 | $3.64 | $2.85 | $2.59 - $3.04 | +27.72% | Beat | -20.0% | 14 | N/A | Feb 3, 2022 | $4.72B |
| Sep 30, 2021 | $2.59 | $2.45 | $2.38 - $2.75 | +5.71% | Beat | -7.2% | 16 | N/A | Nov 4, 2021 | $4.30B |
| Jun 30, 2021 | $2.74 | $2.44 | $2.36 - $2.75 | +12.30% | Beat | +24.5% | 15 | N/A | Aug 5, 2021 | $4.61B |
| Mar 31, 2021 | $3.19 | $3.04 | $2.88 - $3.17 | +4.93% | Beat | +25.1% | 16 | N/A | May 6, 2021 | $4.91B |
| Dec 31, 2020 | $4.55 | $3.16 | $2.77 - $3.51 | +43.99% | Beat | +71.7% | 15 | N/A | Feb 4, 2021 | $5.32B |
| Sep 30, 2020 | $2.79 | $2.54 | $2.40 - $2.70 | +9.84% | Beat | -15.7% | 16 | N/A | Nov 5, 2020 | $3.74B |
| Jun 30, 2020 | $2.20 | $2.07 | $1.69 - $2.35 | +6.28% | Beat | -28.6% | 16 | N/A | Aug 6, 2020 | $3.85B |
| Mar 31, 2020 | $2.55 | $2.29 | $2.09 - $2.49 | +11.35% | Beat | -1.5% | 15 | N/A | May 7, 2020 | $4.25B |
| Dec 31, 2019 | $2.65 | $2.64 | $2.57 - $2.70 | +0.38% | Beat | -1.9% | 15 | N/A | Feb 6, 2020 | $4.22B |
| Sep 30, 2019 | $3.31 | $3.31 | $3.28 - $3.34 | 0.00% | In line | +13.0% | 16 | N/A | Nov 5, 2019 | $4.58B |
| Jun 30, 2019 | $3.08 | $3.06 | $2.96 - $3.22 | +0.65% | Beat | +5.8% | 18 | N/A | Aug 6, 2019 | $4.35B |
| Mar 31, 2019 | $2.59 | $2.59 | $2.53 - $2.62 | 0.00% | In line | -2.3% | 19 | N/A | May 9, 2019 | $4.20B |
| Dec 31, 2018 | $2.70 | $2.62 | $2.50 - $2.80 | +3.05% | Beat | +8.9% | 20 | N/A | Feb 5, 2019 | $4.16B |
| Sep 30, 2018 | $2.93 | $2.93 | $2.89 - $2.98 | 0.00% | In line | +22.1% | 18 | N/A | Nov 6, 2018 | $4.40B |
| Jun 30, 2018 | $2.91 | $2.86 | $2.79 - $2.95 | +1.75% | Beat | +18.3% | 17 | N/A | Aug 2, 2018 | $4.28B |
| Mar 31, 2018 | $2.65 | $2.63 | $2.54 - $2.70 | +0.76% | Beat | +15.2% | 18 | N/A | May 3, 2018 | $4.22B |
| Dec 31, 2017 | $2.48 | $2.41 | $2.26 - $2.59 | +2.90% | Beat | +6.4% | 18 | N/A | Feb 6, 2018 | $3.08B |
| Sep 30, 2017 | $2.40 | $2.37 | $2.32 - $2.40 | +1.27% | Beat | +13.2% | 15 | N/A | Nov 2, 2017 | $3.17B |
| Jun 30, 2017 | $2.46 | $2.44 | $2.38 - $2.53 | +0.82% | Beat | +4.7% | 15 | N/A | Aug 3, 2017 | $3.04B |
| Mar 31, 2017 | $2.30 | $2.23 | N/A | +3.14% | Beat | +5.5% | N/A | N/A | May 2, 2017 | $2.97B |
| Dec 31, 2016 | $2.33 | $2.11 | N/A | +10.43% | Beat | +18.9% | N/A | N/A | Feb 2, 2017 | $2.92B |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was $13.19, down 8.5% from the year before. It was $9.49 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | $13.19 | -8.5% |
| Sep 30, 2025 | $14.42 | +9.6% |
| Sep 30, 2024 | $13.16 | +7.7% |
| Sep 30, 2023 | $12.22 | N/A |
| Sep 30, 2022 | $12.23 | -6.4% |
| Sep 30, 2021 | $13.07 | +28.3% |
| Sep 30, 2020 | $10.19 | -12.8% |
| Sep 30, 2019 | $11.68 | +6.5% |
| Sep 30, 2018 | $10.97 | +15.6% |
| Sep 30, 2017 | $9.49 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,137 | 13 | |
| 2026Q2 | Jun 30, 2026 | 6,456 | 14 | |
| 2026Q1 | Mar 31, 2026 | 8,364 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,198 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,080 | 8 | |
| 2025Q2 | Jun 30, 2025 | 6,962 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,481 | 13 | |
| 2024Q4 | Dec 31, 2024 | 7,077 | 14 |
2026Q3 Earnings Call
Opening remarks
Shawn Bevec Senior Vice President, Investor Relations Good morning, and welcome to BD's earnings call. I'm Shawn Bevec, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the third quarter of fiscal 2026. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our Investor Relations website. Unless otherwise specified, all comparisons will be made on a year-on-year basis versus the relevant fiscal period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted. Also, references to adjusted EPS refer to adjusted diluted EPS. Financials discussed here and included in the earnings release and 10-Q are presented on a continuing operations basis. Prior periods have been recast to reflect the spin-off of our Life Sciences business in combination with Waters, which is now accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of the earnings release and presentation. With that, I will turn it over to Tom.
Thomas Polen Chairman, Chief Executive Officer and President Thank you, Shawn, and good morning, everyone. We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD. And more importantly, the quality of this performance reflects our more focused portfolio beginning to demonstrate the growth and earnings potential we designed it to deliver. Performance was broad-based, reflecting commercial momentum across our key growth platforms, strong operational execution and the expanding impact of BD Excellence. Revenue was $5 billion, up 4.4% with more than 90% of the portfolio delivering high single-digit growth. Performance continues to be driven by ongoing structural improvements across our key growth platforms, where we've been focused on enhancing commercial execution and driving product innovation. This includes double-digit growth across biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, along with strong performance in peripheral vascular disease and Rowa pharmacy automation. As these platforms continue to scale and growth outpaces the broader portfolio, they are becoming more meaningful drivers of top and bottom line performance. We also saw strong U.S. performance in MDS and specimen management, driven by broad underlying utilization as well as share gains.
Frequently Asked Questions About BDX
When is Becton Dickinson and Company's next earnings date?
Becton Dickinson and Company's next earnings report is expected for Feb 8, 2027.
Did BDX beat earnings estimates last quarter?
Yes. Becton Dickinson and Company reported EPS of $4.15 for the quarter ended Sep 30, 2026, above the $4.06 estimate, a 2.22% surprise.
What EPS do analysts expect from BDX next quarter?
The consensus EPS estimate for Becton Dickinson and Company for the quarter ending Dec 31, 2026 is $2.35 from 11 analysts, with estimates from $2.34 to $2.37.
How often does BDX beat earnings estimates?
Becton Dickinson and Company beat the EPS estimate in each of the last 12 quarters, with an average surprise of +5.39%.
BDX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors